GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » Cyclically Adjusted PS Ratio

Societal CDMO (Societal CDMO) Cyclically Adjusted PS Ratio : 0.25 (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Societal CDMO's current share price is $1.10. Societal CDMO's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $4.38. Societal CDMO's Cyclically Adjusted PS Ratio for today is 0.25.

The historical rank and industry rank for Societal CDMO's Cyclically Adjusted PS Ratio or its related term are showing as below:

SCTL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.24   Max: 0.44
Current: 0.25

During the past years, Societal CDMO's highest Cyclically Adjusted PS Ratio was 0.44. The lowest was 0.07. And the median was 0.24.

SCTL's Cyclically Adjusted PS Ratio is ranked better than
92.26% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs SCTL: 0.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Societal CDMO's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.264. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.38 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Societal CDMO Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Societal CDMO's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO Cyclically Adjusted PS Ratio Chart

Societal CDMO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.36 0.32 0.08

Societal CDMO Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.26 0.24 0.10 0.08

Competitive Comparison of Societal CDMO's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societal CDMO's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Societal CDMO's Cyclically Adjusted PS Ratio falls into.



Societal CDMO Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Societal CDMO's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.10/4.38
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Societal CDMO's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Societal CDMO's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.264/129.4194*129.4194
=0.264

Current CPI (Dec. 2023) = 129.4194.

Societal CDMO Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 2.383 100.684 3.063
201509 1.814 100.392 2.339
201512 1.632 99.792 2.117
201603 1.918 100.470 2.471
201606 1.810 101.688 2.304
201609 1.572 101.861 1.997
201612 1.306 101.863 1.659
201703 0.984 102.862 1.238
201706 0.881 103.349 1.103
201709 0.898 104.136 1.116
201712 0.996 104.011 1.239
201803 1.017 105.290 1.250
201806 1.065 106.317 1.296
201809 0.882 106.507 1.072
201812 0.827 105.998 1.010
201903 1.140 107.251 1.376
201906 1.363 108.070 1.632
201909 1.068 108.329 1.276
201912 0.702 108.420 0.838
202003 0.931 108.902 1.106
202006 0.658 108.767 0.783
202009 0.816 109.815 0.962
202012 0.407 109.897 0.479
202103 0.565 111.754 0.654
202106 0.458 114.631 0.517
202109 0.355 115.734 0.397
202112 0.398 117.630 0.438
202203 0.376 121.301 0.401
202206 0.409 125.017 0.423
202209 0.381 125.227 0.394
202212 0.392 125.222 0.405
202303 0.254 127.348 0.258
202306 0.250 128.729 0.251
202309 0.234 129.860 0.233
202312 0.264 129.419 0.264

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Societal CDMO  (NAS:SCTL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Societal CDMO Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Societal CDMO (Societal CDMO) Business Description

Traded in Other Exchanges
N/A
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.
Executives
Bryan M. Reasons director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant director C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr director, officer: Chief Executive Officer
James Charles Miller director 490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens director, 10 percent owner C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc director, 10 percent owner 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks director C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz director 415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p. 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355